TY - JOUR AU - Muhammad Shereen AU - Hafiz Ullah AU - Suliman Khan AU - Nadia Bashir AU - Abeer Kazmi AU - Kainat Saif AU - Muhammad Qudus PY - 2020/07/31 Y2 - 2024/03/29 TI - COVID-19 around the world and the Chinese strategy to cope with SARS-CoV-2 JF - Biomedical Research and Therapy JA - BMRAT VL - 7 IS - 7 SE - Review DO - 10.15419/bmrat.v7i7.618 UR - http://bmrat.org/index.php/BMRAT/article/view/618 AB - SARS-CoV-2, a zoonotic virus, emerged in China causes Coronavirus Disease-2019 (COVID-19). Senior citizens and people with co-infections, genetic diseases, immune-compromised states, and cardiovascular diseases are at higher risk. There is no approved vaccine or drug available to treat COVID-19, although a few antivirals, interferon, and other drugs have reduced viral load in infected patients. However, these drugs have not been significantly effective in European countries. More than 40 different strains of SARS-CoV-2 have been detected in various parts of the world; they might have adapted themselves to the environmental conditions and have become resistant to therapeutic strategies. Many developed and developing countries are facing shortages of surgical masks and other protection tools. So far, the strategies developed by Chinese authorities have efficiently mitigated the SARS-CoV-2 transmission and limited mortality rate to less than 4%, with more than 78,000 people recovered from COVID-19. This review article highlights the pandemic conditions in different parts of the world, as well as possible reasons behind minimal COVID-19 infections and the high mortality rates. It will discuss information about China’s strategies to cope with SARS-CoV-2 which can help other countries to mitigate viral spread and infection. ER -